Reduced cerebral infarct volume (SMD -3.76), mNSS (SMD -2.11), SCr (MD -0.93 mg/dL), inflammation (TNF-α, IL-6, IL-1β; SMD -3.12), apoptosis (SMD -4.52), fibrosis, ALT, AST; improved AMH (SMD 5.39), BV/TV (WMD 14.07%), BBB score (WMD 3.47), wound closure (SMD 3.60), angiogenesis (SMD 4.64), EF (SMD 1.57). This evidence concerns the gene AMH and brain infarction.